Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Dec;50(12):946–949. doi: 10.1136/ard.50.12.946

Deposition of eosinophil cationic protein in vascular lesions in temporal arteritis.

R Hällgren 1, B Gudbjörnsson 1, E Larsson 1, K Fredens 1
PMCID: PMC1004589  PMID: 1768167

Abstract

The possible role of the eosinophil and its cytotoxic granule proteins in the vascular lesions seen in temporal arteritis was elucidated. Sixteen sections of biopsy specimens from arteria temporalis showing giant cell arteritis were stained for eosinophil cationic protein (ECP) by polyclonal antibodies and the immunoperoxidase method. Activated eosinophils were identified by monoclonal antibodies linked to alkaline phosphatase. Activated eosinophils and secreted ECP were seen in all layers of the inflamed vessels and were most evident in necrotic lesions and thrombi. Only a small number of granulocytes seen in the adventitia were immunoreactive for cathepsin G, and no extracellular deposits of this neutrophil granule protein were seen. A few immunoreactive eosinophils were found in the adventitia in two of five negative temporal artery biopsy specimens from patients with polymyalgia rheumatica. All eight coronary artery biopsy specimens with atherosclerotic lesions showed no activated eosinophils or secreted ECP. These findings indicate that eosinophils are involved in the vascular lesion in temporal arteritis and suggest that cytotoxic eosinophil granule proteins may contribute to the necrotic lesions and the development of thrombi.

Full text

PDF
946

Images in this article

947Image
on p.947
947Image
on p.947

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson R., Jonsson R., Tarkowski A., Bengtsson B. A., Malmvall B. E. T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis. Ann Rheum Dis. 1987 Dec;46(12):915–923. doi: 10.1136/ard.46.12.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colley D. G. Eosinophils and immune mechanisms. IV. Culture conditions, antigen requirements, production kinetics and immunologic specificity of the lymphokine eosinophil stimulation promoter. Cell Immunol. 1976 Jun 15;24(2):328–335. doi: 10.1016/0008-8749(76)90216-1. [DOI] [PubMed] [Google Scholar]
  3. Fredens K., Dybdahl H., Dahl R., Baandrup U. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS. 1988 Aug;96(8):711–719. doi: 10.1111/j.1699-0463.1988.tb00934.x. [DOI] [PubMed] [Google Scholar]
  4. Gleich G. J., Frigas E., Loegering D. A., Wassom D. L., Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol. 1979 Dec;123(6):2925–2927. [PubMed] [Google Scholar]
  5. Grove D. I., Mahmoud A. A., Warren K. S. Eosinophils and resistance to Trichinella spiralis. J Exp Med. 1977 Mar 1;145(3):755–759. doi: 10.1084/jem.145.3.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Henson P. M. The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J Immunol. 1971 Dec;107(6):1535–1546. [PubMed] [Google Scholar]
  7. Hubscher T. Role of the eosinophil in the allergic reactions. II. Release of prostaglandins from human eosinophilic leukocytes. J Immunol. 1975 Apr;114(4):1389–1393. [PubMed] [Google Scholar]
  8. Hällgren R., Bjelle A., Venge P. Eosinophil cationic protein in inflammatory synovial effusions as evidence of eosinophil involvement. Ann Rheum Dis. 1984 Aug;43(4):556–562. doi: 10.1136/ard.43.4.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hällgren R., Bjermer L., Lundgren R., Venge P. The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis. 1989 Feb;139(2):373–377. doi: 10.1164/ajrccm/139.2.373. [DOI] [PubMed] [Google Scholar]
  10. Hällgren R., Colombel J. F., Dahl R., Fredens K., Kruse A., Jacobsen N. O., Venge P., Rambaud J. C. Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am J Med. 1989 Jan;86(1):56–64. doi: 10.1016/0002-9343(89)90230-1. [DOI] [PubMed] [Google Scholar]
  11. Hällgren R., Samuelsson T., Venge P., Modig J. Eosinophil activation in the lung is related to lung damage in adult respiratory distress syndrome. Am Rev Respir Dis. 1987 Mar;135(3):639–642. doi: 10.1164/arrd.1987.135.3.639. [DOI] [PubMed] [Google Scholar]
  12. Kierszenbaum F., Villalta F., Tai P. C. Role of inflammatory cells in Chagas' disease. III. Kinetics of human eosinophil activation upon interaction with parasites (Trypanosoma cruzi). J Immunol. 1986 Jan;136(2):662–666. [PubMed] [Google Scholar]
  13. Leiferman K. M., Ackerman S. J., Sampson H. A., Haugen H. S., Venencie P. Y., Gleich G. J. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med. 1985 Aug 1;313(5):282–285. doi: 10.1056/NEJM198508013130502. [DOI] [PubMed] [Google Scholar]
  14. Liang G. C., Simkin P. A., Hunder G. G., Wilske K. R., Healey L. A. Familial aggregation of polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1974 Jan-Feb;17(1):19–24. doi: 10.1002/art.1780170105. [DOI] [PubMed] [Google Scholar]
  15. Lopez A. F., Sanderson C. J., Gamble J. R., Campbell H. D., Young I. G., Vadas M. A. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med. 1988 Jan 1;167(1):219–224. doi: 10.1084/jem.167.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McLaren D. J., McKean J. R., Olsson I., Venges P., Kay A. B. Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro. Parasite Immunol. 1981 Winter;3(4):359–373. doi: 10.1111/j.1365-3024.1981.tb00414.x. [DOI] [PubMed] [Google Scholar]
  17. Olsson I., Venge P., Spitznagel J. K., Lehrer R. I. Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest. 1977 May;36(5):493–500. [PubMed] [Google Scholar]
  18. Owhashi M., Nawa Y. Eosinophil chemotactic lymphokine produced by spleen cells of Schistosoma japonicum-infected mice. Int Arch Allergy Appl Immunol. 1987;82(1):20–25. doi: 10.1159/000234284. [DOI] [PubMed] [Google Scholar]
  19. Speirs R. S., Gallagher M. T., Rauchwerger J., Heim L. R., Trentin J. J. Lymphoid cell dependence of eosinophil response to antigen. II. Location of memory cells and their dependence upon thymic influence. Exp Hematol. 1973;1(3):150–158. [PubMed] [Google Scholar]
  20. Tai P. C., Ackerman S. J., Spry C. J., Dunnette S., Olsen E. G., Gleich G. J. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987 Mar 21;1(8534):643–647. doi: 10.1016/s0140-6736(87)90412-0. [DOI] [PubMed] [Google Scholar]
  21. Tai P. C., Hayes D. J., Clark J. B., Spry C. J. Toxic effects of human eosinophil products on isolated rat heart cells in vitro. Biochem J. 1982 Apr 15;204(1):75–80. doi: 10.1042/bj2040075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tai P. C., Holt M. E., Denny P., Gibbs A. R., Williams B. D., Spry C. J. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin Res Ed) 1984 Aug 18;289(6442):400–402. doi: 10.1136/bmj.289.6442.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tai P. C., Spry C. J., Peterson C., Venge P., Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature. 1984 May 10;309(5964):182–184. doi: 10.1038/309182a0. [DOI] [PubMed] [Google Scholar]
  24. Torisu M., Yoshida T., Ward P. A., Cohen S. Lymphocyte-derived eosinophil chemotactic factor. II. Studies on the mechanism of activation of the precursor substance by immune complexes. J Immunol. 1973 Nov;111(5):1450–1458. [PubMed] [Google Scholar]
  25. Venge P., Dahl R., Hällgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res. 1979;14(4-5):641–649. doi: 10.1016/0049-3848(79)90119-1. [DOI] [PubMed] [Google Scholar]
  26. Weissmann G., Smolen J. E., Korchak H. M. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980 Jul 3;303(1):27–34. doi: 10.1056/NEJM198007033030109. [DOI] [PubMed] [Google Scholar]
  27. Young J. D., Peterson C. G., Venge P., Cohn Z. A. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986 Jun 5;321(6070):613–616. doi: 10.1038/321613a0. [DOI] [PubMed] [Google Scholar]
  28. Zeiger R. S., Twarog F. J., Colten H. R. Histaminase release from human granulocytes. J Exp Med. 1976 Oct 1;144(4):1049–1061. doi: 10.1084/jem.144.4.1049. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES